EXACT Therapeutics AS: Primary insider notification
EXACT Therapeutics AS (EXTX) · publisert 2024-12-19 14:37 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Jonathan Allis 2 a) Position/status Board member | Board member | other | 63 263 | 0 NOK | 2024-12-17 | – | Outside of trading venue | rules · til gjennomgang |
Vedlegg
- Notification of transactions by Primary Insiders (grant options)(20688350.1).pdf (tekst hentet ut)
Meldingstekst
In connection with the appointment of Jonathan Allis to the board of directors of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been granted 63,263 options in the Company which will vest on a quarterly basis.
Please see the attached notification form for further information.
This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com